Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p
Author(s) -
Salil Sharma,
Soban Umar,
François Potus,
Andrea Iorga,
Gabriel Wong,
David Meriwether,
Sandra BreuilsBonnet,
Denise Mai,
Kaveh Navab,
David J. Ross,
Mohamad Navab,
Steeve Provencher,
Alan M. Fogelman,
Sébastien Bonnet,
Srinivasa T. Reddy,
Mansoureh Eghbali
Publication year - 2014
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.114.007405
Subject(s) - medicine , pulmonary hypertension , apolipoprotein b , endocrinology , downregulation and upregulation , lung , hypoxia (environmental) , pharmacology , cholesterol , biochemistry , chemistry , gene , organic chemistry , oxygen
Pulmonary arterial hypertension is a chronic lung disease associated with severe pulmonary vascular changes. A pathogenic role of oxidized lipids such as hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids is well established in vascular disease. Apolipoprotein A-I mimetic peptides, including 4F, have been reported to reduce levels of these oxidized lipids and improve vascular disease. However, the role of oxidized lipids in the progression of pulmonary arterial hypertension and the therapeutic action of 4F in pulmonary arterial hypertension are not well established.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom